MXPA05011886A - Metodos y composiciones para la prevencion y tratamiento de septicemia. - Google Patents

Metodos y composiciones para la prevencion y tratamiento de septicemia.

Info

Publication number
MXPA05011886A
MXPA05011886A MXPA05011886A MXPA05011886A MXPA05011886A MX PA05011886 A MXPA05011886 A MX PA05011886A MX PA05011886 A MXPA05011886 A MX PA05011886A MX PA05011886 A MXPA05011886 A MX PA05011886A MX PA05011886 A MXPA05011886 A MX PA05011886A
Authority
MX
Mexico
Prior art keywords
sepsis
prevention
compositions
treatment
methods
Prior art date
Application number
MXPA05011886A
Other languages
English (en)
Inventor
Tom Eirik Mollnes
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of MXPA05011886A publication Critical patent/MXPA05011886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un metodo para prevenir o tratar la septicemia administrando conjuntamente a un paciente una cantidad para prevenir o tratar la septicemia de uno o mas inhibidores del complemento y una cantidad para prevenir o tratar la septicemia de uno o mas inhibidores de la via CD14. Los inhibidores del complemento son de preferencia anticuerpos que se unen a proteinas del complemento como C5a y las inhiben y los inhibidores de la via CD14 son de preferencia anticuerpos que se unen a componentes de la via CD14 como CD14 y LPS y los inhiben.
MXPA05011886A 2003-05-15 2004-05-14 Metodos y composiciones para la prevencion y tratamiento de septicemia. MXPA05011886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47068103P 2003-05-15 2003-05-15
PCT/US2004/015135 WO2004103294A2 (en) 2003-05-15 2004-05-14 Methods and compositions for the prevention and treatment of sepsis

Publications (1)

Publication Number Publication Date
MXPA05011886A true MXPA05011886A (es) 2006-02-17

Family

ID=33476736

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011886A MXPA05011886A (es) 2003-05-15 2004-05-14 Metodos y composiciones para la prevencion y tratamiento de septicemia.

Country Status (11)

Country Link
US (1) US8329169B2 (es)
EP (2) EP2266606B1 (es)
JP (2) JP4768620B2 (es)
CN (2) CN102258784A (es)
AU (2) AU2004241069B2 (es)
CA (1) CA2524534C (es)
DK (1) DK1628530T3 (es)
ES (2) ES2522525T3 (es)
HK (1) HK1152474A1 (es)
MX (1) MXPA05011886A (es)
WO (1) WO2004103294A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
WO2006063150A2 (en) 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
WO2008154018A2 (en) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
RU2012102021A (ru) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
EP2309001A1 (de) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen
US9358266B2 (en) * 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
CA2797856C (en) 2010-04-30 2018-09-18 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
US9120838B2 (en) 2011-04-18 2015-09-01 Curators Of The University Of Missouri Saccharide conjugates
EP2708233B1 (en) 2011-05-13 2018-06-27 The University of Tokyo Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
MX352621B (es) * 2011-05-19 2017-12-01 Mochida Pharm Co Ltd Diagnostico de la enfermedad infecciosa del tracto respiratorio usando especimenes de sangre.
ES2701075T3 (es) 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
CN102363781A (zh) * 2011-10-19 2012-02-29 海南大学 一种有效抑制小鼠mCD14基因表达的小干扰核糖核酸分子
CN102533758B (zh) * 2011-10-19 2014-04-02 海南大学 一种抑制水牛膜分化抗原14 基因表达的小核糖核酸分子
SG11201403416TA (en) 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
EP4252769A3 (en) 2013-07-09 2023-11-29 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
EP3011345B1 (en) * 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
WO2015054569A1 (en) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
US20160289270A1 (en) * 2013-11-18 2016-10-06 Westfaelische Wilhelms-Universitaet Muenster Methods, Peptides and Antibodies for Preventing, Treating and Diagnosing an Inflammatory Condition
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
SG11201703667SA (en) 2014-11-05 2017-06-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
ES2900998T3 (es) 2015-01-28 2022-03-21 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
WO2017075189A1 (en) 2015-10-27 2017-05-04 University Of Massachusetts Factor h-fc immunotherapy
CN108779171B (zh) 2015-11-24 2022-07-05 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
CN108697759B (zh) 2015-12-16 2022-08-02 Ra制药公司 补体活性的调节剂
WO2017134043A1 (en) * 2016-02-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for neutralising the cytotoxic activity of extracellular histone proteins in subjects suffering from sepsis
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
US20220160820A1 (en) 2019-03-08 2022-05-26 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP2022527508A (ja) 2019-03-29 2022-06-02 ラ ファーマシューティカルズ インコーポレイテッド 補体モジュレータ及び関連方法
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0245993B1 (en) 1986-04-28 1993-05-26 Cetus Oncology Corporation Monoclonal antibodies against c5a and des-arg74-c5a, their production and use
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
DK0485430T3 (da) 1989-08-01 1999-06-14 Scripps Research Inst Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis
US6315999B1 (en) * 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU2694592A (en) 1991-09-30 1993-05-03 Walser, Mackenzie Methods for treatment of free-radical-mediated tissue injury
CA2133758A1 (en) 1992-04-06 1993-10-14 Sanna M. Goyert A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
ATE223230T1 (de) 1993-02-12 2002-09-15 Avant Immunotherapeutics Inc Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
AU695124B2 (en) 1993-05-28 1998-08-06 Scripps Research Institute, The Methods and compositions for inhibiting CD14 mediated cell activation
CN1216992C (zh) * 1994-07-05 2005-08-31 史廷诺研究集团有限公司 免疫调节剂
EP0792162B1 (en) 1994-09-16 2005-11-09 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
CN1171117A (zh) * 1994-12-23 1998-01-21 实验室奥姆公司 Mhc－ⅱ结合和/或mhc－ⅱ模拟分子用于预防和/或治疗炎性疾病的用途
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6042821A (en) 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
CN1226171A (zh) * 1996-05-22 1999-08-18 艾伯塔大学 2－型趋化因子结合蛋白及其使用方法
AU3048797A (en) 1996-10-22 1998-05-15 Chugai Seiyaku Kabushiki Kaisha Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
WO1998039438A1 (fr) 1997-03-07 1998-09-11 Mochida Pharmaceutical Co., Ltd. Composes antisens diriges contre cd14
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
CZ20004256A3 (cs) 1998-05-27 2001-09-12 Gemma Biotechnology Ltd. Indukce antibiotických proteinů a peptidů LAIT/sCD14-proteinem
MXPA01003073A (es) * 1998-09-24 2002-04-24 Univ Minnesota Polipeptido que degrada la proteina c3 complementaria humana a partir de streptococcus pneumoniae.
CN1324244A (zh) * 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
US20030114377A1 (en) 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
CZ20013577A3 (cs) * 1999-04-09 2002-07-17 Basf Aktiengesellschaft Inhibitory komplementních proteáz s nízkou molekulovou hmotností
NZ515374A (en) * 1999-05-18 2004-09-24 Teijin Ltd Remedies or prophylactics for diseases in association with chemokines
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
JP2003522159A (ja) * 2000-02-08 2003-07-22 ザ ユニバーシティ オブ ヴァージニア パテント ファウンデーション 抗Ｃ３ｂ（ｉ）抗体を用いる感染の予防および治療のための方法
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US20040092712A1 (en) 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
WO2001072993A1 (fr) 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Inhibiteur de liaison entre le recepteur de type toll et cd14
ATE404553T1 (de) 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
CA2429467A1 (en) 2000-11-22 2002-05-30 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
WO2002074789A2 (en) * 2001-03-20 2002-09-26 Baylor College Of Medicine Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
SI1425028T1 (sl) 2001-05-16 2010-02-26 Yeda Res & Dev Uporaba inhibitorjev za il-18 za zdravljenje ali prepreäśevanje sepse
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
CN101897969B (zh) * 2003-02-21 2014-04-02 健泰科生物技术公司 补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途

Also Published As

Publication number Publication date
US8329169B2 (en) 2012-12-11
CN1787741A (zh) 2006-06-14
EP1628530B1 (en) 2012-06-06
CA2524534A1 (en) 2004-12-02
CN102258784A (zh) 2011-11-30
US20070274989A1 (en) 2007-11-29
CA2524534C (en) 2012-12-11
WO2004103294A2 (en) 2004-12-02
WO2004103294A3 (en) 2005-05-26
ES2522525T3 (es) 2014-11-14
ES2387275T3 (es) 2012-09-19
AU2004241069B2 (en) 2010-09-09
JP2006528981A (ja) 2006-12-28
EP2266606B1 (en) 2014-09-10
EP1628530B8 (en) 2012-08-01
AU2004241069A1 (en) 2004-12-02
EP2266606A1 (en) 2010-12-29
EP1628530A4 (en) 2007-08-29
JP2011105747A (ja) 2011-06-02
HK1152474A1 (en) 2012-03-02
EP1628530A2 (en) 2006-03-01
DK1628530T3 (da) 2012-07-23
AU2010249190B2 (en) 2013-02-28
CN1787741B (zh) 2011-08-17
AU2010249190A1 (en) 2011-01-06
JP4768620B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2006024018A3 (en) Compositions for treating nociceptive pain
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
TW200727894A (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ATE524190T1 (de) Hemmung von cholera-toxinen durch galatooligosacchariden (gos)
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
TW200503668A (en) Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights